Atsushi Miyamoto

Closest collaborators

The 25 strongest of 64 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

1. Hideki Motobayashi · 4 shared papers, 2022–2025 · strength 0.72
   • Paper Octogenarians with lower BMI have comparatively poor survival in potentially resectable pancreatic cancer: outcomes ove… DOI 10.1016/j.suronc.2025.102248↗
   • Paper Short-term serial circulating tumor DNA assessment predicts therapeutic efficacy for patients with advanced pancreatic … DOI 10.1007/s00432-023-05594-1↗
   • Paper Radiographic duodenal invasion is associated with poor prognosis and early recurrence in patients with pancreatic ducta… DOI 10.1016/j.ejso.2023.06.012↗
2. Yuji Kitahata · 4 shared papers, 2022–2025 · strength 0.72
   • Paper Octogenarians with lower BMI have comparatively poor survival in potentially resectable pancreatic cancer: outcomes ove… DOI 10.1016/j.suronc.2025.102248↗
   • Paper Short-term serial circulating tumor DNA assessment predicts therapeutic efficacy for patients with advanced pancreatic … DOI 10.1007/s00432-023-05594-1↗
   • Paper Radiographic duodenal invasion is associated with poor prognosis and early recurrence in patients with pancreatic ducta… DOI 10.1016/j.ejso.2023.06.012↗
3. Manabu Kawai · 4 shared papers, 2022–2025 · strength 0.72
   • Paper Octogenarians with lower BMI have comparatively poor survival in potentially resectable pancreatic cancer: outcomes ove… DOI 10.1016/j.suronc.2025.102248↗
   • Paper Short-term serial circulating tumor DNA assessment predicts therapeutic efficacy for patients with advanced pancreatic … DOI 10.1007/s00432-023-05594-1↗
   • Paper Radiographic duodenal invasion is associated with poor prognosis and early recurrence in patients with pancreatic ducta… DOI 10.1016/j.ejso.2023.06.012↗
4. Tomohiro Yoshimura · 3 shared papers, 2023–2025 · strength 0.57
   • Paper Octogenarians with lower BMI have comparatively poor survival in potentially resectable pancreatic cancer: outcomes ove… DOI 10.1016/j.suronc.2025.102248↗
   • Paper Short-term serial circulating tumor DNA assessment predicts therapeutic efficacy for patients with advanced pancreatic … DOI 10.1007/s00432-023-05594-1↗
   • Paper Radiographic duodenal invasion is associated with poor prognosis and early recurrence in patients with pancreatic ducta… DOI 10.1016/j.ejso.2023.06.012↗
5. Soichiro Morinaga · 4 shared papers, 2020–2026 · strength 0.54
   • Paper Usefulness of an S-1 dosage formula for predicting adverse events in adjuvant chemotherapy for curatively resected panc… DOI 10.1007/s00535-026-02413-5↗
   • Paper Neoadjuvant S-1 With Concurrent Radiotherapy Followed by Surgery for Borderline Resectable Pancreatic Cancer: A Phase I… DOI 10.1097/sla.0000000000004535↗
   • Paper Tolerability of Nab-Paclitaxel Plus Gemcitabine as Adjuvant Setting in Japanese Patients With Resected Pancreatic Cance… DOI 10.1097/mpa.0000000000001702↗
6. Shoji Nakamori · 7 shared papers, 2015–2021 · strength 0.52
   • Paper Tolerability of Nab-Paclitaxel Plus Gemcitabine as Adjuvant Setting in Japanese Patients With Resected Pancreatic Cance… DOI 10.1097/mpa.0000000000001702↗
   • Paper [A Case of Long-Term Survival after Total Pancreatectomy for Recurrent Pancreatic Cancer in the Remnant Pancreas after … PMID 30914550↗
   • Paper CA19-9 level determines therapeutic modality in pancreatic cancer patients with para-aortic lymph node metastasis. DOI 10.1016/j.hbpd.2018.01.004↗
7. Ken‐ichi Okada · 3 shared papers, 2022–2024 · strength 0.49
   • Paper Short-term serial circulating tumor DNA assessment predicts therapeutic efficacy for patients with advanced pancreatic … DOI 10.1007/s00432-023-05594-1↗
   • Paper Radiographic duodenal invasion is associated with poor prognosis and early recurrence in patients with pancreatic ducta… DOI 10.1016/j.ejso.2023.06.012↗
   • Paper Circulating Tumor DNA as a Potential Prognostic Marker in Patients with Borderline-Resectable Pancreatic Cancer Undergo… DOI 10.1245/s10434-021-10985-0↗
8. Hiroki Yamaue · 3 shared papers, 2022–2024 · strength 0.49
   • Paper Short-term serial circulating tumor DNA assessment predicts therapeutic efficacy for patients with advanced pancreatic … DOI 10.1007/s00432-023-05594-1↗
   • Paper Radiographic duodenal invasion is associated with poor prognosis and early recurrence in patients with pancreatic ducta… DOI 10.1016/j.ejso.2023.06.012↗
   • Paper Circulating Tumor DNA as a Potential Prognostic Marker in Patients with Borderline-Resectable Pancreatic Cancer Undergo… DOI 10.1245/s10434-021-10985-0↗
9. Motoki Miyazawa · 3 shared papers, 2022–2024 · strength 0.49
   • Paper Short-term serial circulating tumor DNA assessment predicts therapeutic efficacy for patients with advanced pancreatic … DOI 10.1007/s00432-023-05594-1↗
   • Paper Radiographic duodenal invasion is associated with poor prognosis and early recurrence in patients with pancreatic ducta… DOI 10.1016/j.ejso.2023.06.012↗
   • Paper Circulating Tumor DNA as a Potential Prognostic Marker in Patients with Borderline-Resectable Pancreatic Cancer Undergo… DOI 10.1245/s10434-021-10985-0↗
10. Katsuhiko Uesaka · 3 shared papers, 2020–2026 · strength 0.44
    • Paper Usefulness of an S-1 dosage formula for predicting adverse events in adjuvant chemotherapy for curatively resected panc… DOI 10.1007/s00535-026-02413-5↗
    • Paper Neoadjuvant S-1 With Concurrent Radiotherapy Followed by Surgery for Borderline Resectable Pancreatic Cancer: A Phase I… DOI 10.1097/sla.0000000000004535↗
    • Paper Relationship between surgical R0 resectability and findings of peripancreatic vascular invasion on CT imaging after neo… DOI 10.1186/s12885-020-07698-0↗
11. Hirochika Toyama · 3 shared papers, 2020–2026 · strength 0.44
    • Paper Usefulness of an S-1 dosage formula for predicting adverse events in adjuvant chemotherapy for curatively resected panc… DOI 10.1007/s00535-026-02413-5↗
    • Paper Neoadjuvant S-1 With Concurrent Radiotherapy Followed by Surgery for Borderline Resectable Pancreatic Cancer: A Phase I… DOI 10.1097/sla.0000000000004535↗
    • Paper Relationship between surgical R0 resectability and findings of peripancreatic vascular invasion on CT imaging after neo… DOI 10.1186/s12885-020-07698-0↗
12. Atsushi Shimizu · 2 shared papers, 2023–2024 · strength 0.33
    • Paper Short-term serial circulating tumor DNA assessment predicts therapeutic efficacy for patients with advanced pancreatic … DOI 10.1007/s00432-023-05594-1↗
    • Paper Radiographic duodenal invasion is associated with poor prognosis and early recurrence in patients with pancreatic ducta… DOI 10.1016/j.ejso.2023.06.012↗
13. Akira Fukutomi · 2 shared papers, 2021–2026 · strength 0.33
    • Paper Usefulness of an S-1 dosage formula for predicting adverse events in adjuvant chemotherapy for curatively resected panc… DOI 10.1007/s00535-026-02413-5↗
    • Paper Tolerability of Nab-Paclitaxel Plus Gemcitabine as Adjuvant Setting in Japanese Patients With Resected Pancreatic Cance… DOI 10.1097/mpa.0000000000001702↗
14. Seiko Hirono · 2 shared papers, 2022–2023 · strength 0.31
    • Paper Radiographic duodenal invasion is associated with poor prognosis and early recurrence in patients with pancreatic ducta… DOI 10.1016/j.ejso.2023.06.012↗
    • Paper Circulating Tumor DNA as a Potential Prognostic Marker in Patients with Borderline-Resectable Pancreatic Cancer Undergo… DOI 10.1245/s10434-021-10985-0↗
15. Mitsugu Sekimoto · 4 shared papers, 2016–2019 · strength 0.30
    • Paper [A Case of Long-Term Survival after Total Pancreatectomy for Recurrent Pancreatic Cancer in the Remnant Pancreas after … PMID 30914550↗
    • Paper CA19-9 level determines therapeutic modality in pancreatic cancer patients with para-aortic lymph node metastasis. DOI 10.1016/j.hbpd.2018.01.004↗
    • Paper Successful conversion surgery for unresectable pancreatic cancer with peritoneal metastases after neoadjuvant albumin-b… DOI 10.1007/s13691-017-0311-0↗
16. Tadafumi Asaoka · 4 shared papers, 2015–2018 · strength 0.26
    • Paper CA19-9 level determines therapeutic modality in pancreatic cancer patients with para-aortic lymph node metastasis. DOI 10.1016/j.hbpd.2018.01.004↗
    • Paper Prognostic impact of nodal statuses in patients with pancreatic ductal adenocarcinoma. DOI 10.1016/j.pan.2017.01.003↗
    • Paper Prognostic impact of preoperative NLR and CA19-9 in pancreatic cancer. DOI 10.1016/j.pan.2015.10.006↗
17. Amane Takahashi · 1 shared paper, 2026 · strength 0.23
    • Paper Usefulness of an S-1 dosage formula for predicting adverse events in adjuvant chemotherapy for curatively resected panc… DOI 10.1007/s00535-026-02413-5↗
18. Kazunaga Ishigaki · 1 shared paper, 2026 · strength 0.23
    • Paper Usefulness of an S-1 dosage formula for predicting adverse events in adjuvant chemotherapy for curatively resected panc… DOI 10.1007/s00535-026-02413-5↗
19. Narikazu Boku · 1 shared paper, 2026 · strength 0.23
    • Paper Usefulness of an S-1 dosage formula for predicting adverse events in adjuvant chemotherapy for curatively resected panc… DOI 10.1007/s00535-026-02413-5↗
20. Naoto Gotohda · 1 shared paper, 2026 · strength 0.23
    • Paper Usefulness of an S-1 dosage formula for predicting adverse events in adjuvant chemotherapy for curatively resected panc… DOI 10.1007/s00535-026-02413-5↗
21. Atsuyuki Maeda · 1 shared paper, 2026 · strength 0.23
    • Paper Usefulness of an S-1 dosage formula for predicting adverse events in adjuvant chemotherapy for curatively resected panc… DOI 10.1007/s00535-026-02413-5↗
22. Yukiyasu Okamura · 1 shared paper, 2026 · strength 0.23
    • Paper Usefulness of an S-1 dosage formula for predicting adverse events in adjuvant chemotherapy for curatively resected panc… DOI 10.1007/s00535-026-02413-5↗
23. Yousuke Nakai · 1 shared paper, 2026 · strength 0.23
    • Paper Usefulness of an S-1 dosage formula for predicting adverse events in adjuvant chemotherapy for curatively resected panc… DOI 10.1007/s00535-026-02413-5↗
24. Mitsuhiro Fujishiro · 1 shared paper, 2026 · strength 0.23
    • Paper Usefulness of an S-1 dosage formula for predicting adverse events in adjuvant chemotherapy for curatively resected panc… DOI 10.1007/s00535-026-02413-5↗
25. Norihisa Takakura · 2 shared papers, 2020–2022 · strength 0.21
    • Paper Neoadjuvant S-1 With Concurrent Radiotherapy Followed by Surgery for Borderline Resectable Pancreatic Cancer: A Phase I… DOI 10.1097/sla.0000000000004535↗
    • Paper Relationship between surgical R0 resectability and findings of peripancreatic vascular invasion on CT imaging after neo… DOI 10.1186/s12885-020-07698-0↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.